The test stands out as the first successful molecular diagnostic tool for ME, a development that has been long anticipated by many healthcare providers and patients. This new tool opens up the possibility for differentiation between mild and severe cases of ME.
ME is a complex disorder characterized by extreme fatigue that lasts for at least six months and that can’t be fully explained by an underlying medical condition. The fatigue worsens with physical or mental activity but doesn’t improve by resting.
The results from the November study may also allow healthcare providers to potentially predict how patients will respond to certain medications, which could help them make treatment more personalized (and hopefully more effective) in the future. The findings were published in the journal Scientific Reports.
One of the study’s authors, Alain Moreau, PhD, a professor in the department of biochemistry and molecular medicine at the Université de Montréal, is hopeful the research can be used to diagnoses ME patients. “There [are] no laboratory test or biomarkers used for the diagnosis or prognosis of ME/CFS. We believe that our test is the first of its kind,” Moreau tells Verywell. “Clinicians usually establish their diagnosis by excluding all possible causes that could explain the symptoms associated with ME/CFS.”
This test, he hopes, will result in quicker diagnoses, and faster, more effective treatments.
How It Works
In order to test a patient, researchers attached an inflatable arm cuff to a patient’s arm, which then provided mechanical stimulation. The result causes post-exertional malaise, one of the most common symptoms of ME, and provides an exact molecular signature. This makes it possible to differentiate between ME patients and those without the condition, as well as from patients living with related conditions such as fibromyalgia.
Next comes a blood test. The test detected a change in abundance of 11 microRNAs in patients’ blood compared with blood drawn before the test. MicroRNAs are small non-coding RNA molecules that act inside cells to regulate gene expression—and have been the subject of research interest as potential diagnostic tools for several conditions.
Most of these 11 microRNAs found were involved in regulating immunity, which supports the idea that immune dysfunction plays a key role in ME. The findings are the first step in developing a molecular diagnostic test for the disease.
An increase or reduction of some of the microRNAs measured in the test can also help predict the patient’s therapeutic response to certain drugs, which improves the chances of finding the right therapy to personalize treatment.
The research team is now validating the test in other groups and continuing clinical trials. The test may allow for early detection of ME in people with persistent post-COVID-19 symptoms that are very similar to ME, making earlier intervention possible, the researchers add.
Lingering COVID-19 Symptoms
More than six months into the global COVID-19 pandemic, many who contract the virus are not fully recovering from their illness. Up to 35% of people diagnosed with COVID-19 were not back to their normal selves two to three weeks after testing positive, according to a July report by the Centers for Disease Control and Prevention (CDC).
Of the 292 people the CDC surveyed on post-COVID-19 recoveries, 35% reported fatigue. These patients who have yet to fully recover are commonly referred to as COVID-19 “long-haulers.”
In a November 2020 letter to the editor of the journal Med Hypotheses, a group of doctors voiced their concerns about the lingering effects on COVID-19 patients. The doctors recommended more proactive testing for CFS in recovered COVID-19 patients.
Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, has speculated that many long-haulers will develop ME. Previous research shows ME can be triggered by other infectious illnesses like mononucleosis, Lyme disease, and severe acute respiratory syndrome (SARS), which is another coronavirus disease.
There was an error. Please try again.
“[The pandemic] will bring a huge number of new [ME/CFS] patients, and some of them are relatively young. That will create some devastating impacts for themselves and their families,” Moreau told TheScientist. “That’s why we need to hurry and hope that we will convince governments and funding agencies to [put more funding into the field].”
The information in this article is current as of the date listed, which means newer information may be available when you read this. For the most recent updates on COVID-19, visit our coronavirus news page.
